Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution

Eligible studies

All studies originally published in English and confirmed as focused on tumor subtype characterization in Hispanics/Latinas were included in this review.

Publication search

We searched the published literature using PubMed (NIH, Bethesda, MD). To identify studies we queried medical subject headings (MeSH): “breast cancer subtypes” and “Latinas” that retrieved 29 publications, from which 8 were included in this paper. We also searched for “breast cancer intrinsic subtypes” and “Hispanic,” and this search retrieved 62 papers, from which 19 were eligible for this review; 8 of them were already included from the last search. Finally, we used “breast cancer subtypes distribution” and “Hispanic,” and we found 59 publications, from which 4 were included in this paper. The last search was on July 11, 2017. All resulted studies were retrieved, and cited publications were checked for related publications. We limited our electronic search to original English-language publications and published since 2007 to include only studies from the last 10 years.

Definition of breast cancer intrinsic subtypes

In 2000, Perou and colleagues (14) published the first article classifying breast cancer into intrinsic subtypes based on gene expression profiles. Using a cDNA microarray of 65 surgical specimens from 42 different individuals, Perou and colleagues defined a list of “intrinsic” genes that have consistent expression in tumors from the same patient (i.e., primary and metastasis) but differ between tumors from different patients. This analysis revealed 4 main molecular subtypes: luminal, HER2-enriched, basal-like, and normal-like. ER⁺ tumors, identified as luminal, are characterized by increased expression of genes from luminal cells, such as GATA, X-box binding protein 1, trefoil factor 3, and hepatocyte nuclear factor (15). The luminal group is, in turn, divided into luminal A and B subtypes, with the luminal B expressing higher levels of proliferation-related genes and often expressing HER1, HER2, and/or cyclin E1, whereas luminal A subtype have a higher expression of genes such as the estrogen receptor gene (ESR1) and GATA3 (16–19). The estrogen receptor-negative (ER⁻) group is divided into basal-like, HER2-enriched, and normal-like. The basal-like subgroup is characterized by expression of basement membrane cytokeratins such as CK5/6 and CK17; and lacks the expression of ESR1 and its coexpressed genes. Patients with BRCA1 mutations have been associated with the development of basal-like tumors (20–22). The HER2-enriched subtype is associated with high expression of ERBB2 and genes in the 17q22.24 locus including GRB7 and MIEN1 (23–26). The normal-like subtype is still a matter of debate as some researchers have considered it as an artifact due to contamination with normal tissue adjacent to the tumor (27). Its molecular profile is characterized by the expression of genes typical of basal epithelial cells and adipose cells and low expression of genes from luminal epithelial cells (14, 28, 29).

The clinical implication of this new classification became apparent 1 year later when the same group, using a larger set of tumors, demonstrated that each of the intrinsic subtypes was associated with different prognoses (14, 29, 30). The HER2-enriched and basal-like subtypes have the poorest prognosis when compared to the luminal subtypes. Among luminal tumors, the luminal B has worst prognosis compared with luminal A, which is expected given its high expression of cell proliferation genes (31–36).

Breast cancer in Hispanic/Latina women

The terms “Hispanic” or “Latino” are generally used to refer to people from Mexico, Cuba, Puerto Rico, Central or South America. Latinos constitute the largest, youngest, and fastest-growing minority group in the United States (37). An estimated 55 million people living in the United States self-identified as Hispanic or Latino (38), representing 17% of the total population in United States in 2014, and predicted to increase to 35% by the year 2050 (39). Hispanic/Latinos is a heterogeneous group that originated from the admixture of Native American, European, and African ancestries. Hispanic/Latinos can self-identify as any race defined by the 2000 United States Census (37, 38, 40, 41).

Fejerman and colleagues (42) showed the first evidence of association between genetic ancestry and breast cancer risk in Hispanic/Latinas from the San Francisco Bay area. They found an increased risk of breast cancer for every 25% increase in European ancestry (OR = 1.79; 95% CI, 1.28–2.79) that remained significant after adjusting for known risk factors for the disease (OR = 1.39; 95% CI, 1.06–2.11). Two years later they retested the association in women from Mexico to explore the possibility that the original finding was due to environmental factors. In this population, they replicated the original association finding that for every 25% increase in European ancestry (modeled as a continuous variable), there was a 20% increase in breast cancer risk (95% CI, 1.03–1.41; ref. 43). Fejerman and colleagues (41) also showed that genetic ancestry was associated with breast cancer-specific survival in a sample of Hispanic/Latinas from California. Women with more than 50% Native American ancestry had a mortality hazard that almost doubled that of Hispanic/Latinas with 50% or less of Native American ancestry.

Recently, a population-based study using SEER registries found an increase in the risk of breast cancer mortality in Hispanic/Latina women (44, 45). Ooi and colleagues (8), also based on SEER data, found that Hispanic/Latina women have 1.1-fold greater risk of breast cancer-specific mortality compared to NHW women after adjusting for disease characteristics, treatments, and some socioeconomics characteristics such as poverty and education (8).

Differences in mortality among population groups might be explained by a combination of differences in socioeconomic and biological factors (46). For example, Hispanic/Latinas are usually diagnosed at more advanced stages of the disease, possibly as a consequence of poor access to mammography screening and delayed follow-up of an abnormal mammography (44, 45). Additionally, some studies have suggested that differences in language spoken, cultural beliefs, and other factors contribute to inconsistencies in the screening and follow up of an abnormal mammogram even in populations with similar access to screening (47–49). Regarding biological factors, population-based studies in the United States have reported that Hispanic/Latina women are more likely to have ER⁻ tumors, compared with NHW women (50, 51), similar to what has been reported for AA women (44).

Distribution of intrinsic subtypes of breast cancer in Hispanic/Latina women

Different available surrogates for molecular classification of breast cancer into intrinsic subtypes have been proposed (Table 1). The basic and most used classification includes the evaluation of hormone receptors (HR) ER and progesterone receptor (PR) and the evaluation of HER2 by IHC. The St. Gallen surrogates included Ki67 to better stratify luminal tumors.

The prevalence of breast cancer intrinsic subtypes varies according to race/ethnicity (Table 2). There have been multiple studies evaluating the distribution of IHC-based tumor subtypes in Hispanic/Latinas using population-based registries from SEER (52, 53). These studies report a higher prevalence of triple negative tumors in Hispanic/Latinas compared to NHW women, with percentages in Hispanic/Latinas ranging between 14% and 15% depending on the study. Using polytomous logistic regression modeling, the HR⁺/HER2⁻ as the reference subtype, and NHW as the reference explanatory variable (52), they have also reported a higher risk of developing triple negative tumors and HR⁻/HER2⁺ tumors among Hispanic/Latinas (OR = 1.3; 95% CI, 1.2–1.5 and OR = 1.4; 95% CI, 1.2–1.6, respectively).

Similar results have been observed in studies that used data from the California Cancer Registry (CCR; refs. 51, 54–56). The prevalence of triple negative subtype in these studies ranged between 13% and 17%. Concordant with previous reports, some of these studies also observed that Hispanic/Latina women were more likely to be diagnosed with triple negative disease (OR = 1.23; 95% CI, 1.14–1.34) when compared to NHW (54). Banegas and colleagues (51) used data from the CCR and analyzed the association between breast cancer subtype and patients attributes and found that foreign-born Hispanic/Latina women were significantly more likely than U.S.-born Hispanic/Latina women to be diagnosed with HR⁻/HER2⁺ subtype (OR = 1.17; 95% CI, 1.02–1.35). Moreover, lower socioeconomic status (SES) was also associated with a higher risk for triple negative and HR⁻/HER2⁺ subtypes. Even though this study included a large number of Hispanic/Latina women, they were all residents of California and therefore mostly of Mexican descent (51, 57). This result cannot be generalized to all Hispano/Latino subpopulations.

Plasilova and colleagues (58) used The National Cancer Database (NCDB) to analyze the characteristics of 38,813 breast tumors defined by the expression of HR and HER2 in women diagnosed between 2010 and 2011. They observed that among Hispanic/Latina women, the luminal A subtype was the most prevalent (67.4%) followed by triple negative (14.8%), luminal B (11.9%), and HER2-enriched (5.8%). Sineshaw and colleagues (59) also used the NCDB data. They analyzed 260,174 breast cancer cases from that database and found that the prevalence of triple negative subtype in Hispanic/Latina was 13.8%. This latter analysis showed that Hispanic/Latina women had 1.26 times greater odds of being diagnosed with HER2-enriched subtype (OR = 1.26; 95% CI, 1.16–1.37) and 1.17 times greater odds of being diagnosed with triple negative subtype (OR = 1.17; 95% CI, 1.11–1.24) using NHWs as reference population and the luminal A subtype as reference subtype.

Population-based studies such as The Life After Cancer Epidemiology (LACE) study and the 4-Corners Breast Cancer Study are valuable sources to explore ethnic differences in the distribution of breast cancer subtypes. Hines and colleagues (60) reviewed pathology reports and established tissue microarrays in a sample of 188 women (69 Hispanic/Latina women and 119 NHW women) who were Colorado participants in the 4-Corners Breast Cancer Study. Five immunohistochemically markers (ER, PR, HER2, EGFR, and CK5/6) were evaluated using standard IHC staining methods. They also found that Hispanic/Latina women had a higher prevalence of ER⁻ tumors (ER⁻/PR⁺/HER2⁺, ER⁻/PR⁺/HER2⁻, ER⁻, PR⁻/HER2⁺, ER⁻/PR⁻/HER2⁻) compared to NHW women (36.2% vs. 22.7%). Specifically, Hispanic/Latina women were reported to have a higher proportion of triple negative subtype compared to NHW (17.4% and 15.1%, respectively), but this difference was not statistically significant. Kroenke and colleagues (61) analyzed 1,635 breast cancer patients from the Pathways and LACE study and found a higher prevalence of triple-negative subtype (14%) when compared with the prevalence of this subtype in NHW (11.0%).

The study by Sweeney and colleagues (62) is the largest study to date describing the distribution of intrinsic subtypes based on PAM50 classification (27). This study included 1,319 women and observed an increased prevalence of the most aggressive intrinsic subtypes such as HER2-enriched (15.6%) and luminal B (24.0%) in Hispanic/Latina women when compared to women from other races/ethnicities.

Hispanic/Latina women have also been reported to have a relatively high proportion of HER2⁺ tumors (ER⁺/PR⁺/HER2⁺, ER⁺/PR⁻/HER2⁺, ER⁻/PR⁺/HER2⁺, ER⁻/PR⁻/HER2⁺), even after adjustment for tumor characteristics such as grade, stage, ER status, and risk factors such as number of children and alcohol consumption (38). Hines and colleagues (60) observed that Hispanic/Latina women had a significantly higher prevalence of HER2⁺ tumors (HR⁺/HER2⁺ and HR⁻/HER2⁺) compared with NHWs (31.95% vs. 14.3%, respectively, P < 0.01). Specifically they observed a higher prevalence of the HER2-enriched subtype in Hispanic/Latina compared with NHWs (14.5% vs. 5.9%). These results are concordant with those in Kwan and colleagues (63), which included 2,280 women from the LACE study. These women were diagnosed with invasive breast cancer between 1997 and 2000. Breast cancer subtypes were defined by the expression of HR and HER2. They reported that HER2-enriched subtype tumors (HR⁻/HER2⁺) were more common in Hispanic/Latinas (OR = 2.19; 95% CI, 1.16–4.13) and Asians (OR = 2.02; 95% CI, 1.05–3.88) than NHWs. Howlader and colleagues (52) also observed a high prevalence of HER2-enriched tumors but in an early-onset group (11.4%) compared with an older group (6.47%). Banegas and colleagues (51) found that foreign-born Hispanic women were significantly more likely to be diagnosed with HR⁻/HER2⁺ than HR⁺/HER2⁻ breast cancer (OR = 1.17; 95% CI, 1.02–1.35) compared with U.S.-born Hispanic women.

We found one hospital-based study from United States. Singh and colleagues (64) analyzed the distribution of intrinsic subtypes of breast cancer in a sample of 2,120 patients from five major racial/ethnic groups: NHW, AA, and Hispanics/Latinos from the United States, Chinese (Jilin, China), and Indian (Delhi, India), and according to age (early-onset ≤40 years and older group ≥50 years and older). This study included patient race data from the Memorial Sloan Kettering Cancer Center for AA patients, New York University School of Medicine for NHW patients, The University of Texas MD Anderson Cancer Center for Hispanic/Latino patients, The First Hospital of Jilin University (China) for native Chinese patients, and Rajiv Gandhi Cancer Institute & Research Centre (Delhi, India) for native Indian patients. The IHC data on HR and HER2 was retrieved from each participating study to classify breast cancer into intrinsic subtypes. They found that the prevalence of triple negative breast cancer was higher in Indians (23.3%) followed by AA (22.8%), Hispanic/Latina (19.7%), Chinese (14.3%), and NHW (9.8%). Similar percentages were observed for triple-negative disease in the early onset group (31.57%, 23.15%, 22.77%, 12.2%, and 16.66% respectively, for the same population groups). In the older onset group, the prevalence of triple-negative subtype was higher in AA (22.52%), followed by Indians (21.55) and Hispanic/Latina (14.7%).

Studies in Hispanic/Latina women from Latin American countries

All studies described above had been conducted in individuals born or residing in the United States. However, similar results have been reported for Hispanic/Latina women in Latin America. All of the studies described below are hospital-based.

Lara-Medina and colleagues (65) analyzed the expression of HR and HER2 by IHC in 2,074 Hispanic/Latino breast cancer patients from the National Cancer Institute in Mexico City and were diagnosed between 1998 and 2008. They reported a high prevalence of triple-negative subtype (23.1%). This percentage is similar to the prevalence reported in AA women (23%–30%), and higher than that in NHW women (10%–13%). This study included 20.4% of patients with a family history of breast cancer and therefore the presence of BRCA1 mutations could be a contributing factor to the high prevalence of triple-negative tumors reported.

Martinez and colleagues (66) assessed tumor subtype prevalence in 1,041 women of Mexican descent enrolled in a binational breast cancer study. They recruited patients in two hospitals in the United States (The Arizona cancer center and the M.D Anderson Cancer Center); and three in Mexico (the Universidad de Sonora, the Instituto Tecnológico de Sonora and the Universidad de Guadalajara). The prevalence of triple negative subtype was 16.7% overall but a higher proportion of ER⁻ (HR⁻/HER2⁺ and HR⁻/HER2⁻) tumors was observed for women in Mexico compared with those in the United States.

Srur-Rivero and colleagues (67) analyzed 199 breast cancer patients from the San Juan de Dios Hospital in Costa Rica diagnosed between 2009 and 2010. This hospital is a reference cancer treatment center for Costa Rica's South Central Region. Breast cancer subtypes were defined by the expression of HR and HER2. The median age at diagnosis was 53 years. The prevalence of the triple-negative subtype was 17.4%.

In Brazil, de Macedo Andrade and colleagues (68) evaluated the expression of HR, HER2, and Ki67 following the recommendations of St. Gallen panel from 2011 (69) to assign breast tumors from 633 women into intrinsic subtypes. Data from pathology reports were obtained from the “Fundação de Assistência da Paraíba” (FAP) public hospital of Campina Grande, Paraíba, Brazil. They reported luminal B as the most prevalent subtype (44.61%), followed by luminal A (23.79%), triple negative (17.10%), and HER2-enriched (14.5%). Even though triple-negative intrinsic subtype was found as the third most prevalent, the percentage reported in this study is similar to what has been reported previously in Hispanic/Latina women (51, 60, 65, 67).

Ortiz and colleagues (70) found that the two most prevalent subtypes were luminal A (61.8%) and triple negative (17.3%) in a sample of 663 patients diagnosed with invasive breast cancer between 2002 and 2005 at the I. Gonzalez Martinez Oncologic Hospital and the Auxilio Mutuo Hospital in Puerto Rico.

Several studies have been conducted in Colombia. Our group analyzed the distribution of breast cancer–intrinsic subtypes in 301 patients from the National Cancer Institute in Colombia (INC) diagnosed between 2008 and 2012 (71). The INC has a double role in cancer control in Colombia: (i) It advices the Ministry of Health on all national cancer-related issues (policies, strategies, surveillance for cancer control and prevention); and (ii) it is the National Comprehensive Reference Center for cancer treatment. The mean age at diagnosis was 56.6 years. Using the different surrogates proposed by the St. Gallen panel of experts in 2011 (69) and in 2013 (72), we found that following the recommendations of the St. Gallen 2013 surrogates, the luminal B subtype was the most prevalent (37.2%). Although using the 2011 St. Gallen surrogates the most prevalent subtype was luminal A (36.21%), an enrichment of luminal B was noticed when compared with the basic classification that included the evaluation of HR and HER2 (30.23% vs. 15.95%, respectively). The high prevalence of luminal B subtype is concordant with the findings reported by Macedo Andrade and colleagues (68). We also observed high proportion of triple-negative tumors (20.6%). We found a higher proportion of African ancestry in patients with triple-negative tumors, which is consistent with the literature (11, 19, 46, 73). Gomez and colleagues (74) analyzed the distribution of breast cancer intrinsic subtypes in 328 clinic-based patients from Medellin, Colombia, diagnosed between January 2009 and December 2010. The mean age at diagnosis for this study was 52.9 years. They followed St. Gallen 2011 surrogates (69) and found that the luminal B represented more than 50% of the intrinsic subtypes identified.

In Peru, Vallejos and colleagues (75) analyzed 1,198 breast cancer patients diagnosed between January 1, 2000, and December 21, 2002, in the Instituto Nacional de Enfermedades Neoplásicas in Lima and retrieved the expression of HR and HER2. They observed a high prevalence of more aggressive intrinsic subtypes, such as triple negative (21.3%) and HER2-enriched (16.2%).

Despite the hererogeneity in the reported prevalence of different molecular subtypes among Hispanic/Latina women, most studies suggest a high prevalence of the more aggressive subtypes (i.e., ER⁻ and luminal B; Table 2). This heterogeneity may be related in part to the differences in the classification methods used, biases associated with clinic/hospital-based studies (as opposed to registry-based studies), and to differences in the genetic ancestry from the Hispanic/Latina women analyzed (76, 77).